Article Text

PDF
Randomized clinical trial
Detemir is non-inferior to NPH insulin in women with pregestational type 2 diabetes and gestational diabetes mellitus
  1. Priyathama Vellanki,
  2. Guillermo Umpierrez
  1. Division of Endocrinology, Metabolism and Lipids, Emory University School of Medicine, Atlanta, Georgia, USA
  1. Correspondence to : Dr Guillermo Umpierrez, Division of Endocrinology, Metabolism and Lipids, Emory University School of Medicine, 49 Jesse Hill Jr. Dr. SE, Atlanta, GA 30308, USA; geumpie{at}emory.edu

Statistics from Altmetric.com

Commentary on: OpenUrlCrossRef

Context

Pregestational diabetes (pre-GDM) and gestational diabetes mellitus (GDM) affect as many as 1.3% and 9.2% of pregnancies, respectively.1 ,2 Hyperglycaemia during pregnancy has been associated with a two to three times increased risk of congenital defects and with the rate of macrosomia and stillbirth in the fetus and preeclampsia in the mother compared with pregnancies in a non-diabetic population.3 The risk of maternal and fetal complications is closely related to poor glycemic control, in particular postprandial hyperglycaemia.3 Current guidelines recommend intensification of glycemic control for at least 3 months before pregnancy in women with type 1 and type 2 diabetes.3 To achieve these goals, most patients are treated with multidose insulin injections with a combination of basal and prandial …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.